Free Trial
NASDAQ:ATHA

Athira Pharma (ATHA) Stock Price, News & Analysis

Athira Pharma logo
$0.63
+0.02 (+3.98%)
(As of 12:37 PM ET)

About Athira Pharma Stock (NASDAQ:ATHA)

Key Stats

Today's Range
$0.57
$0.67
50-Day Range
$0.42
$3.30
52-Week Range
$0.41
$4.30
Volume
6.31 million shs
Average Volume
1.63 million shs
Market Capitalization
$24.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.83
Consensus Rating
Hold

Company Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
55th Percentile Overall Score

ATHA MarketRank™: 

Athira Pharma scored higher than 55% of companies evaluated by MarketBeat, and ranked 518th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Athira Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Athira Pharma has only been the subject of 4 research reports in the past 90 days.

  • Read more about Athira Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Athira Pharma are expected to grow in the coming year, from ($2.57) to ($1.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Athira Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Athira Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Athira Pharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Athira Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    4.41% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 0.64%, indicating that investor sentiment is improving.
  • Dividend Yield

    Athira Pharma does not currently pay a dividend.

  • Dividend Growth

    Athira Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.41% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 0.64%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for ATHA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Athira Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,033.00 in company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Athira Pharma's insider trading history.
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

ATHA Stock News Headlines

Athira Pharma to present results from Phase 2/3 LIFT-AD trial
Rigged election?
Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late.
Athira Pharma files $300M mixed securities shelf
Mizuho Downgrades Athira Pharma (ATHA)
Hold Rating on Athira Pharma Amid Strategic Pivot and Clinical Uncertainty
Athira Pharma to Cut About 70% of Workforce
Athira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical Progress
See More Headlines

ATHA Stock Analysis - Frequently Asked Questions

Athira Pharma's stock was trading at $2.43 on January 1st, 2024. Since then, ATHA stock has decreased by 74.3% and is now trading at $0.6250.
View the best growth stocks for 2024 here
.

Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings data on Thursday, August, 1st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.05.

Athira Pharma (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

Athira Pharma's top institutional investors include Bristlecone Advisors LLC (0.88%). Insiders that own company stock include Perceptive Advisors Llc, Glenna Mileson, Mark James Litton, Andrew Gengos, Kelly A Romano, Hans Moebius, Mark Worthington, Rachel Lenington and James A Johnson.
View institutional ownership trends
.

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Palantir Technologies (PLTR), Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META).

Company Calendar

Last Earnings
8/01/2024
Today
11/04/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHA
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.83
High Stock Price Target
$22.00
Low Stock Price Target
$0.50
Potential Upside/Downside
+2,113.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-117,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
30,828,000
Market Cap
$24.03 million
Optionable
Optionable
Beta
2.82
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:ATHA) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners